A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices

Otsuka Pharmaceutical Development & Commercialization, Inc.1,200 enrolled

Overview

The purpose of this clinical research study is to evaluate if Aripiprazole will prove to be effective, safe and well tolerated in the treatment of patients with schizophrenia who are treated in a general psychiatric setting.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

1,200

Conditions

Schizophrenia

Interventions

AripiprazoleDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical DSM-IV diagnosis of schizophrenia * Patients being managed as outpatients, for whom an alteration in medication is clinically reasonable or initiation of antipsychotics is required Exclusion Criteria: * Risk of committing suicide, diagnosis of schizoaffective disorder, bipolar disorder, depression with psychotic syptoms, or organic brain syndromes * Prisoners or subjects compulsory detained

Locations (20)

Local Institution

Antwerp, Belgium

Local Institution

Brussels, Belgium

Local Institution

Diest, Belgium

Outcomes

Primary Outcomes

Clinical Global Impression-Improvement at endpoint

Secondary Outcomes

Patients' and caregivers' medication preference

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.